Article Sidebar

Submitted
Jul 17, 2023
Accepted
Aug 13, 2023
Published
Oct 23, 2023
Download
pdf
Statistic
Read Counter : 49 Download : 37

Downloads

Download data is not yet available.

Main Article Content

Abstract

The NS3 protein plays an important role in HCV replication, where its N-terminal domain acts as a protease to process most of the viral polypeptides. In addition, this protein also functions as an RNA helicase and NTPase and triggers liver fibrosis which accelerates the development of liver disease. Resistance-associated substitution (RAS) is commonly detected in failed DAA regimens. RAS has been identified in proteins involved in HCV infection, one of which is NS3. Thus, this study has a design to identify natural compounds that are able to target the HCV NS3 protein. To identify natural compounds, a ligand-based and structure-based pharmacophore model to the cavity of the active protein site was generated after virtual screening and molecular docking. Three compounds namely stigmasterol, gamma mangostin, and erycristagallin have been found as HCV antiviral candidates that target the NS3 protein with a lower binding affinity than the original ligand. Based on ADMET analysis, the three compounds have high absorption in the small intestine. Analysis of the cytotoxicity of stigmasterol compounds did not have the potential to be mutagenic. The LD50 value of stigmasterol is also lower than other compounds. However, the stigmasterol compound has a lower MRTD.

Keywords

HCV NS3 molecular docking pharmacophore modeling

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
1.
Rahayu R, Erlina L, Ratnoglik SL, Yasmon A, Fadilah, Paramita RI. Identification of Antiviral Compounds against Hepatitis C Virus (HCV) targeting NS3 protein by Pharmacophore Modeling, Molecular Docking, and ADMET Approach. EKSAKTA [Internet]. 2023Oct.23 [cited 2023Dec.2];23(04):523-36. Available from: https://eksakta.ppj.unp.ac.id/index.php/eksakta/article/view/448

References

  1. Alawode, T. T., Lajide, L., Olaleye, M., & Owolabi, B. (2021). Stigmasterol and β-Sitosterol: Antimicrobial Compounds in the Leaves of Icacina trichantha identified by GC–MS. Beni-Suef University Journal of Basic and Applied Sciences, 10(1), 80.
  2. Ansori, A., Kharisma, V., Parikesit, A. A., Dian, F., Probojati, R., Rebezov, M., Scherbakov, P., Burkov, P. V, Zhdanova, G., Mikhalev, A., Antonius, Y., Pratama, M., Sumantri, N., Sucipto, T., & Zainul, R. (2022). Bioactive Compounds from Mangosteen (Garcinia mangostana L.) as an Antiviral Agent via Dual Inhibitor Mechanism against SARSCoV- 2: An in Silico Approach. Pharmacognosy Journal, 14, 85–90.
  3. Anwar, T., Kumar, P., & Khan, A. U. (2021). Molecular Docking for Computer-Aided Drug Design. In M. S. Coumar (Ed.), Molecular Docking for Computer-Aided Drug Design. Academic Press.
  4. B, U. R., Tandon, H., Pradhan, M. K., Adhikesavan, H., Srinivasan, N., Das, S., & Jayaraman, N. (2020). Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener. ACS Omega, 5(20), 11553–11562.
  5. Bajorath, J. (2022). Deep Machine Learning for Computer-Aided Drug Design. Frontiers in Drug Discovery, 2.
  6. Bakrim, S., Benkhaira, N., Bourais, I., Benali, T., Lee, L.-H., El Omari, N., Sheikh, R. A., Goh, K. W., Ming, L. C., & Bouyahya, A. (2022). Health Benefits and Pharmacological Properties of Stigmasterol. Antioxidants (Basel, Switzerland), 11(10).
  7. Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016). BDDCS, the Rule of 5 and drugability. Advanced Drug Delivery Reviews, 101, 89–98.
  8. Bissantz, C., Kuhn, B., & Stahl, M. (2010). A medicinal chemist’s guide to molecular interactions. Journal of Medicinal Chemistry, 53(14), 5061–5084.
  9. Caputo, V., Diotti, R. A., Boeri, E., Hasson, H., Sampaolo, M., Criscuolo, E., Bagaglio, S., Messina, E., Uberti-Foppa, C., Castelli, M., Burioni, R., Mancini, N., Clementi, M., & Clementi, N. (2020). Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. Virology Journal, 17(1), 103.
  10. Chatel-Chaix, L., Baril, M., & Lamarre, D. (2010). Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses, 2(8), 1752–1765.
  11. Deng, L., Nagano-Fujii, M., Tanaka, M., Nomura-Takigawa, Y., Ikeda, M., Kato, N., Sada, K., & Hotta, H. (2006). NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. The Journal of General Virology, 87(Pt 6), 1703–1713.
  12. Flores-Holguín, N., Frau, J., & Glossman-Mitnik, D. (2021). In Silico Pharmacokinetics, ADMET Study and Conceptual DFT Analysis of Two Plant Cyclopeptides Isolated from Rosaceae as a Computational Peptidology Approach. Frontiers in Chemistry, 9.
  13. Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. Pharmaceuticals (Basel, Switzerland), 15(5).
  14. Goto, K., Roca Suarez, A. A., Wrensch, F., Baumert, T. F., & Lupberger, J. (2020). Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. International Journal of Molecular Sciences, 21(9).
  15. Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019). ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm, 10(1), 148–157.
  16. Guedes, I. A., de Magalhães, C. S., & Dardenne, L. E. (2014). Receptor-ligand molecular docking. Biophysical Reviews, 6(1), 75–87.
  17. Han, Y., Zhang, J., Hu, C. Q., Zhang, X., Ma, B., & Zhang, P. (2019). In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities. Frontiers in Pharmacology, 10, 434.
  18. Huang, H.-C. (2020). Direct-acting antivirals: The answer to hepatitis C virus reactivation after organ transplantation? In Journal of the Chinese Medical Association: JCMA, 83(4), 319–320.
  19. Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017). Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Scientific Reports, 7(1), 46277.
  20. LaPlante, S. R., Padyana, A. K., Abeywardane, A., Bonneau, P., Cartier, M., Coulombe, R., Jakalian, A., Wildeson-Jones, J., Li, X., Liang, S., McKercher, G., White, P., Zhang, Q., & Taylor, S. J. (2014). Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus. Journal of Medicinal Chemistry, 57(5), 2074–2090.
  21. Marliyana, S. D., Wibowo, F. R., Handayani, D. S., Kusumaningsih, T., Suryanti, V., Firdaus, M., & Annisa, E. N. (2021). Stigmasterol and Stigmasterone from Methanol Extract of Calophyllum soulattri Burm. F. Stem Bark. Jurnal Kimia Sains Dan Aplikasi, 24(4), 108-113.
  22. Martínez, L. (2015). Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PloS One, 10(3), e0119264.
  23. Medina-Franco, J. L. (2021). Grand Challenges of Computer-Aided Drug Design: The Road Ahead. Frontiers in Drug Discovery, 1.
  24. Njamen, D., Talla, E., Mbafor, J., Fomum, Z., Kamanyi, A., Mbanya, J. C., Cerdá-Nicolás, M., Giner, R., Recio, M., & Rios, J.-L. (2003). Anti-inflammatory activity of erycristagallin, a pterocarpene from Erythrina mildbraedii. European Journal of Pharmacology, 468, 67–74.
  25. Opo, F. A. D. M., Rahman, M. M., Ahammad, F., Ahmed, I., Bhuiyan, M. A., & Asiri, A. M. (2021). Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Scientific Reports, 11(1), 4049.
  26. Organization, W. H. (2021). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. WHO, 53 (9).
  27. Patil, P., Agrawal, M., Almelkar, S., Jeengar, M. K., More, A., Alagarasu, K., Kumar, N. V, Mainkar, P. S., Parashar, D., & Cherian, S. (2021). In vitro and in vivo studies reveal α-Mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus. Virology Journal, 18(1), 47.
  28. Perpiñán, E., Caro-Pérez, N., García-González, N., Gregori, J., González, P., Bartres, C., Soria, M. E., Perales, C., Lens, S., Mariño, Z., Londoño, M. C., Ariza, X., Koutsoudakis, G., Quer, J., González-Candelas, F., Forns, X., & Pérez-Del-Pulgar, S. (2018). Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. Journal of Viral Hepatitis, 25(12), 1515–1525.
  29. Pinzi, L., & Rastelli, G. (2019). Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 20(18).
  30. Proekt, A., & Hemmings, H. C. (2019). Pharmacology and Physiology fo. In H. C. Hemmings & T. D. Egan (Eds.), Pharmacology and Physiology for Anesthesia (Second Edition), Elsevier.
  31. Romano, K. P., Laine, J. M., Deveau, L. M., Cao, H., Massi, F., & Schiffer, C. A. (2011). Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease. Journal of Virology, 85(13), 6106–6116.
  32. Salahudeen, M. S., & Nishtala, P. S. (2017). An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharmaceutical Journal (SPJ), 25(2), 165–175.
  33. Soekamto, N. H., Firdaus, Ahmad, F., & Appa, F. E. (2019). Potential of stigmasterol from EtOAc extract Melochia umbellata (Houtt) Stapf var. Visenia as Dengue Antivirus. Journal of Physics: Conference Series, 1341(3), 32044.
  34. Sorbo, M. C., Cento, V., Di Maio, V. C., Howe, A. Y. M., Garcia, F., Perno, C. F., & Ceccherini-Silberstein, F. (2018). Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 37, 17–39.
  35. Temml, V., Garscha, U., Romp, E., Schubert, G., Gerstmeier, J., Kutil, Z., Matuszczak, B., Waltenberger, B., Stuppner, H., Werz, O., & Schuster, D. (2017). Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening. Scientific Reports, 7, 42751.
  36. Tijjani, H., Olatunde, A., Adegunloye, A. P., & Ishola, A. A. (2022). Chapter 14 - In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins. In C. B. T.-C. D. D. Egbuna (Ed.), Drug Discovery Update (pp. 313–333). Elsevier.
  37. Tyagi, R., Singh, A., Chaudhary, K. K., & Yadav, M. K. (2022). Pharmacophore modeling and its applications. In D. B. Singh & R. K. Pathak (Eds.), Bioinformatics (pp. 269–289). Academic Press.
  38. Vanmierlo, T., Bogie, J. F. J., Mailleux, J., Vanmol, J., Lütjohann, D., Mulder, M., & Hendriks, J. J. A. (2015). Plant sterols: Friend or foe in CNS disorders? Progress in Lipid Research, 58, 26–39.
  39. Vázquez, J., López, M., Gibert, E., Herrero, E., & Luque, F. J. (2020). Merging Ligand-Based and Structure-Based Methods in Drug Discovery: An Overview of Combined Virtual Screening Approaches. Molecules (Basel, Switzerland), 25(20).

Most read articles by the same author(s)